The Top 50 Healthcare Technology CEOs of 2020

The Healthcare Technology Report is pleased to announce The Top 50 Healthcare Technology CEOs of 2020. Now more than ever, with our global community impacted by a severe pandemic, the importance of the healthcare technology field is at the forefront. An extensive process was run to evaluate the hundreds of CEOs who were nominated this year. These CEOs lead exemplary organizations in the fields of medical devices, biotech, healthcare analytics, healthcare software and other related areas. We gathered data on each nominee’s professional background and assessed them across several key areas including breadth of leadership experience in the healthcare technology industry, level of expertise and domain knowledge in their particular field, depth of their executive team’s experience, and consistency of organizational performance. Congratulations to each of the Top 50 Healthcare Technology CEOs of 2020.


1. Marc Casper, Thermo Fisher Scientific

Marc Casper is the CEO of Thermo Fisher Scientific, a company that delivers innovative technologies, purchasing convenience, and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, and Invitrogen. Since he was appointed the company’s Chief Executive Officer in 2009, he has overseen several acquisitions, most notably Life Technologies in 2013, which made Thermo Fisher Scientific a global leader in the market for precision laboratory equipment. He has been celebrated for driving the outstanding execution of a growth strategy that has resulted in significant value creation for customers, colleagues, and shareholders. Prior to joining Thermo Fisher, Casper served as President and Chief Executive Officer as well as the Director of Kendro Laboratory Products. Before this, he worked for clinical diagnostics provider Dade Behring, where he was the President of the Americas. Casper began his career as a strategy consultant at Bain & Company and later joined Bain Capital. Today, he balances his role with being a Trustee on the US-China Business Council, a nonprofit aimed at strengthening commercial ties between the US and China.


2. Tom Polen, BD

Tom Polen was appointed Chief Executive Officer of Becton, Dickinson, and Company (BD) in 2019. This announcement came after 17 years at the global medical technology New Jersey-based company. Polen first joined BD in 1999 after growing an early phase start-up that was subsequently purchased by the company. While he left in 2004 to work at Baxter International, a company focused on innovative solutions to treat hemophilia, kidney disease, immune disorders, and other chronic conditions; he rejoined BD in 2009. His new tenure began as the President of BD Preanalytical Systems. He was appointed President of BD in April 2017 and named Chief Operating Officer in October 2018. Today, as CEO, Polen has led the company through the COVID-19 pandemic, receiving FDA approval for a new diagnostic test that will enable US hospitals to screen for the virus and get results in under three hours. Polen is an active benefactor and volunteer for the Children’s Tumor Foundation, as well as several national and local associations committed to helping patients with breast cancer.


3. Brian Tyler, McKesson Corporation

Brian Tyler is a 22-year veteran of McKesson and has served in a variety of roles, including Chief Operating Officer and President, before being appointed Chief Executive Officer in 2019. During his tenure, Tyler has led almost every significant business opportunity within the company, as well as McKesson’s corporate strategy and business development unit. Headquartered in Irving, Texas McKesson distributes pharmaceuticals, medical-surgical supplies, as well as health and beauty care products throughout North America. The company also develops, implements, and supports software that facilitates the integration of data throughout the health enterprise. Tyler has served as Chairman of the Management Board of McKesson Europe, where he was part of the team that drove revenue growth to $27.3 billion. His roles also span leading the North American Pharmaceuticals Distribution Services, Corporate Strategy and Business Development, US Pharmaceuticals, McKesson Medical-Surgical, McKesson Specialty Care Solutions and McKesson Distribution Solutions. Before joining McKesson, Tyler spent three years at Integral as a Senior Associate of Health Care Consulting. He balances his role with being an Executive Board Member of the Healthcare Distribution Alliance and a Board Member at the International Federation of Pharmaceutical Wholesalers.


4. Bob Segert, athenahealth

Since coming to athenahealth following the company’s combination with Virence Health in 2019, Bob Segert has helped the company embrace a fresh new start. Bob has a passion for understanding and delivering on the needs of the customer, a relentless commitment to operational excellence, and a track record for driving outstanding results. A leading provider of network-enabled services for medical groups and health systems nationwide, athenahealth continues to flourish under Segert's leadership as it creates a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all through the company’s proven expertise, modern and adaptable technology, open and connected network, and data insights. The Massachusetts-based company is also taking several measures to help healthcare providers quickly make informed decisions and ease workflow constraints to support its customers who are on the frontlines of the pandemic. As a long-time software and services executive, Segert's experience spans 20+ years across a multitude of industries in the US and around the world. Segert is also a board member of EPAM Systems. Before joining athenahealth, he was the Chairman and CEO at Virence Health, Executive Chairman at Aspect Software, President and CEO at Expert Global Solutions, President and CEO at GXS, and Vice President of EDS.


5. Omar Ishrak, Medtronic

In 2011, Omar Ishrak was hired away from GE Healthcare to effect a turnaround at Medtronic. It was the second time in the company's 62-year history that an outsider effectively took over the reins at the medical device company, but a decision they would come to celebrate. As the Chief Executive Officer, Ishrak has doubled the company's annual revenues and its market capitalization has increased by more than $100 billion during his tenure. The industry veteran announced his retirement for April 2020, though to overlook his achievements here would be remiss. The Bangladeshi-born CEO's distinct style and forward-thinking led to one of the company's most significant mergers when Medtronic acquired Irish tech company Covidien in 2015. At $49.9 billion it is the largest medtech merger in the history of the industry. Ishrak established Medtronic's Diversity Networks during his time at the company. Meanwhile, Medtronic has also been celebrated as a firm driving global change by building workplaces that prioritize women. He is currently Executive Chairman and Chairman of the Board at Medtronic and Chairman of the Board at Intel.


6. Rusty Frantz, NextGen Healthcare

As the President and Chief Executive Officer of NextGen Healthcare, it’s Rusty Frantz's mission to lead the transformation of the company into a client-focused, innovative, and purpose-driven solutions provider. Headquartered in Irvine, California, NextGen is the leading EHR and healthcare practice software solution for ambulatory care providers. Under Frantz's leadership, the company has established a strong workplace culture, while enhancing its capabilities and continuing to improve its ability to deliver value to clients as they navigate the complex world of healthcare. Prior to leading NextGen, he spent eight years at CareFusion where Frantz's most recent role was as the Senior Vice President and General Manager of the Global Dispensing division. Before this, he was the Chief Technology Officer and a co-founder of OutPurchase, a provider of cloud-based procurement solutions and services. He began his career as one of the first employees at Omnicell, a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the healthcare continuum.


7. Caren Mason, STAAR Surgical

Caren Mason was appointed President and Chief Executive Officer of STAAR Surgical in 2015, after having served on the Board of Directors since 2014. Over 35 years, Mason has built a reputation for excellence with a career that spans leadership roles at large corporations, public companies, and start-up technologies across the life sciences, healthcare information, and medical device sectors. In her previous leadership positions, Mason developed customer-centric cultures that drove commercial success while maintaining a strong focus on quality systems, regulatory affairs, and compliance. Headquartered in Monrovia, California STAAR Surgical designs, manufactures and markets implantable lenses for the eye with companion delivery systems. In addition to her role at STAAR, Mason is a director of HealthTell, an early-stage life sciences company. She also serves as Chair on the executive committee for the UCSD Moores Cancer Center Board of Visitors. Prior to this, she was the CEO of Verinata Health, President and CEO of Quidel Corporation, President and CEO at MiraMedica, CEO of eMed Technologies, General Manager of GE Healthcare, and Senior Vice President at Bayer Healthcare. She spent 11-years as Director of Sales and Marketing at Baxter International.


8. Timothy Wright, MiMedx Group

Timothy Wright has dedicated his career to improving peoples' healthcare and lives by transforming companies across the industry. In his role as MiMedx's Chief Executive Officer, Wright has embraced the challenge of overhauling the company's culture and optimizing its patient-care mission. Headquartered in Marietta, Georgia, MiMedx is a biopharmaceutical company developing, manufacturing, and marketing regenerative biologics for multiple healthcare sectors. The company's goal is to serve people with severe chronic wounds that cannot heal without advanced clinical intervention. Today, Wright is preparing the company for relisting on the Nasdaq stock market. With over 30 years of experience in the healthcare industry, spanning pharmaceutical, biotech, and medical device sectors, he brings to MiMedx a track record that is results-oriented— and most of all, unparalleled. While his tenure at the company has just ticked over to a year, MiMedx's employees have already noted an improvement in transparency and ethical leadership and a renewed passion for being part of a team that is making an impact on peoples' everyday lives. Before joining MiMedx, Wright held positions at M2GEN, Teva Pharmaceuticals, Ohio State University's Comprehensive Cancer Center, Mallinckrodt Covidien, AAI Pharma, Elan Pharmaceuticals, and Cardinal Health.


9. Matthew Hawkins, Waystar

Matthew Hawkins is the Chief Executive Officer at market-leading technology company Waystar. The company’s cloud-based software platform eases administrative burdens and helps providers get paid with minimal chance of claim denial or getting bounced back from insurance companies. Passionate about modernizing the healthcare experience, Hawkins has seen the company grow and now boasts a 98% first-pass clean claim rate across its network. Over the last five years, he has helped identify and develop more than $4.5 billion in healthcare technology-related investments. Notably, Hawkins led the milestone sale of Waystar to EQT and CPPIB in 2019, with Bain Capital retaining a minority stake in the company. Before joining Waystar, Hawkins was President of Sunquest Information Systems, leading its transformation into a global leader in laboratory diagnostic informatics. Before this, he was CEO and Board Member at Vitera Healthcare Solutions, CEO and Board Member of SirsiDynix, Vice President and General Manager of Henry Schein, Management Consultant at McKinsey & Company, Project Manager at Tenfold Corporation as well as an Analyst at EDS.


10. Zane Burke, Livongo

As Chief Executive Officer of Livongo, Zane Burke is determined to change the healthcare system for those living with chronic conditions. Through a combination of data science, behavior enablement, and clinical impact, the California-based company empowers people with chronic and behavioral health conditions to live better and healthier lives. Burke joined the Livongo executive team in 2018, leaving his 18-year tenure as CEO of Cerner, a $5.1 billion publicly traded healthcare technology company. Widely regarded as playing a pivotal role in landing two of Cerner's most significant EHR contracts, Burke's addition to the Livongo team signals an exciting future for the startup as it rapidly expands. For Burke, his move to the company was all about making an impact on the over 150 million Americans suffering from chronic illnesses that could benefit from Livongo. Today, he leads with an integrated business mindset while prioritizing client relationships across all healthcare industry segments. In addition to this role, Burke sits on the Boards of the College of Healthcare Information Management Executives and Truman Medical Centers.


11. Stéphane Bancel, Moderna

Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Previously, he served for five years as CEO of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Stéphane served as Asia-Pacific Sales and Marketing Director for bioMérieux. He currently serves on the board of directors of Qiagen N.V. and is a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston.


12. Peter Kirk, Sermo

Peter started his mission to build a cutting-edge healthcare research company in 2000 with a team of just five employees. Powered by innovative technology and a customer-first approach, the business quickly evolved to become a global data collection powerhouse and the most trusted social platform for doctors with over 300 employees in nine offices and a worldwide network of over one million healthcare professionals. Under Peter’s leadership, the physician social platform Sermo was acquired in 2012 to transform physician engagement and healthcare data collection and democratize insights to help move medicine forward. Sermo leverages its capabilities to help amplify the voice of physicians globally by publishing results that help the healthcare industry at-large and create a single source of information. Peter holds a Masters in Finance from London Business School. “Unique insights and opportunities are at the core of our business. We are always looking for ways to innovate around the way our healthcare partners connect with and learn from physicians through our platform,” said Erin Fitzgerald, Senior Vice President, Marketing at Sermo. “Even more resounding during these challenging times amidst the pandemic, Peter’s leadership has been a powerful force of good bringing together and growing a global platform where physicians can collaborate, support one another and share powerful insights to help support medicine’s continuous evolution.”


13. Alex Gorsky, Johnson & Johnson

Alex Gorsky is Chairman and CEO of Johnson & Johnson, a position which he has held since 2012. He is the seventh person to serve in the joint position since the Company went public in 1944. Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management. In 2001, Alex was appointed President of Janssen, and in 2003, he was promoted to Company Group Chairman of Johnson & Johnson’s pharmaceuticals business for the regions of Europe, the Middle East and Africa. Between 2004 and 2008, Alex led Novartis’ pharmaceuticals business in North America, later returning to Johnson & Johnson as a key senior leader. He earned his undergraduate degree from West Point and an MBA from The Wharton School of Business.


14. Bill Moss, Seven Bridges

As the Chief Executive Officer of Seven Bridges, Bill Moss uses his vast experience as an industry thought leader in transforming the company, bringing it to the forefront of the bioinformatics revolution. Headquartered in Massachusetts, Seven Bridges is the leading infrastructure and data analytics company accelerating precision medicine. Since joining the company as its Chief Operations Officer in 2018, Moss has gone on to become its President of Commercial Operations before being appointed CEO in 2019. Moss's proven track record for leading emerging insurtech health science technology organizations to long-term operational success and substantial corporate valuations reach beyond Seven Bridges. As a leader, he is first and foremost an innovator with a great vision. Moss's acute understanding of where the bioinformatics field is going and what the industry needs to accelerate scientific discovery is unparalleled. Notably, Moss was a part of the founding executive team that formed TechRx, where he led the company through acquisitions by NCDHealth, Per Se Technologies, and ultimately McKesson Corporation for more than $2.3 billion. Prior to joining Seven Bridges, Moss was the Executive Vice President of Business Development and Corporate Strategy at TruthMD/MedFax, Senior Vice President of Sales and Marketing at MFX, Chief Business Development Officer at Delphi Technology, Vice President of Strategic Solutions Group at AMS, and the Vice President of Sales at Revive Technology.


15. Judy Faulkner, Epic Systems

Judy Faulkner is the CEO and founder of Epic Systems, a healthcare software company located in Wisconsin. She founded the Company in 1979, with the original name of Human Services Computing, with $70,000 in backing from friends and family. Since then, the Company has never raised venture capital or private equity capital. Faulkner has stated she has no intentions of taking the company public. She is reported to be one of the wealthiest self-made women in America with an estimated net worth of $3.5 billion. Epic Systems now holds the medical records of over 200 million people. She and her family currently own 43% of the Company. Faulkner received a bachelor's degree in mathematics from Dickinson College and a master's degree in computer science from the University of Wisconsin–Madison.


16. Susan Wood, VIDA

Dr. Susan Wood is a celebrated industry veteran with over 20 years of experience and a knack for championing cutting edge clinical solutions to the marketplace. Since being appointed President and CEO of VIDA in 2009, Dr. Wood has led the charge in bringing AI to all aspects of medicine, including at VIDA, the leader in pulmonary imaging analytics, which recently joined Nuance AI Marketplace as a technology partner. Her impact is felt industry-wide, with Dr. Wood's pulmonary research pinpointing the need for volumetric, quantitative CT imaging for pulmonary diagnosis and treatment planning. Before joining VIDA, Dr. Wood was the Executive Vice President of Marketing and Technology at Vital Images and led new product development at R2 Technology where she was instrumental in the production and market development of the first-ever FDA-cleared computer-aided detection (CAD) product for lung nodule detection in multidetector computed tomography (MDCT). Notably, she has been issued six patents in the field of computer-aided detection and quantitative imaging, authored several papers and has spoken at numerous conferences as a trusted voice in three-dimensional imaging of the thorax, quantitative imaging, and computer-aided detection.


17. Jean-Jacques Bienaime, BioMarin

Jean-Jacques Bienaime is currently the Chairman and CEO at BioMarin. He joined the company in May 2005 as CEO and member of the board of directors, bringing with him over 25 years of experience in the biotechnology and pharmaceutical industries. Under his leadership, the market capitalization of BioMarin went from around $450 million in May 2005 to approximately $16 billion in the summer of 2016. From November 2002 to April 2005, Jean-Jacques served as Chairman, CEO, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. He currently serves on the boards of Incyte Corporation and Vital Therapies, which are both biotechnology companies and The Biotech Industry Organization.


18. Jason Gorevic, Teladoc Health

Jason Gorevic joined Teladoc Health as CEO in 2009. Previously he was the Chief Marketing and Product Officer and President of WellPoint and before that was Chief Sales and Marketing Officer of BlueCross BlueShield. Jason, a graduate of the University of Pennsylvania, started his career with Oxford Health Plans. He has grown Teladoc Health at an astounding rate. Since 2015, revenue has gone from $77 million to $123 million to $233 million and to $418 million in each of the subsequent years while steadily holding net income at close to breakeven. Founded in 2002, Teladoc Health is the nation’s first and largest provider of telehealth services with more than 3 million members nationwide and an average response time of 22 minutes.


19. Paul Dabrowski, Synthego

Synthego was co-founded by brothers Paul and Michael Dabrowski in 2011 after the two left SpaceX, where they both worked as rocket engineers. Today, Paul is the Chief Executive Officer of Synthego. This genetic engineering startup makes synthetic RNA, optimizing the use of the CRISPR gene-editing techniques to make engineered biological therapies accessible to all patients. Under Paul's leadership, the Silicon Valley-based company has gone from inception to its world-class commercial offering for genome engineering. Today, the company has several thousand customers across 45 countries, over 250 employees, and more than $150 million in funding. In 2019, Synthego was tapped by the National Institutes of Health to focus on a project by the National Institute on Aging which looks at Alzheimer's disease research. The company's swift expansion and assignment by the NIH is a testament to Paul's leadership but also Synthego's mission of making genome engineering more accessible to scientists and drug developers. Before founding the company in 2011, Paul was the lead digital designer for the Falcon 9 rocket and Dragon spacecraft at SpaceX. He also founded a mobile software company and designed a portable electron microscope for DNA sequencing.


20. Brent Shafer, Cerner

Brent Shafer is Chairman CEO of Cerner, which he joined in 2018. Previously, he was the CEO of Philips North America, where he oversaw a health technology portfolio that included a broad range of solutions and services covering patient monitoring, imaging, clinical informatics, sleep and respiratory care as well as a group of market-leading consumer-oriented brands. Brent was also previously the CEO of the global Philips Home Healthcare Solutions business. Earlier in his career, he served in senior leadership positions at other companies, including GE Medical Systems, Hill-Rom and Hewlett-Packard. He serves on the board of No Barriers USA, a nonprofit that organizes life-changing experiences for youth, veterans and people with disabilities.


21. Eric Ostertag, Poseida Therapeutics

In 2015, Dr. Eric Ostertag directed Poseida's spin-out from Transposagen Biopharmaceuticals and has been the Chief Executive Officer and a member of the Board of Directors ever since. With an eye for developing off-the-shelf cell therapies, Dr. Ostertag has been the driving force behind Poseida's next-generation, non-viral gene engineering technologies. Headquartered in San Diego, the company's mission is to find cures for diseases like prostate, multiple myeloma, and other cancers, by developing both autologous and allogeneic gene therapies capable of achieving effective and positive results in patient health. Here, Dr. Ostertag has developed Poseida's clinical program to include developing next-generation in-vivo and ex-vivo gene therapies, including liver-directed gene therapies, and nanoparticle-based candidates. One of his greatest achievements is his instrumental role in the development of the Cas-CLOVER Site-Specific Gene Editing System, which can perform highly efficient multiplexed gene editing, enabling fully allogeneic CAR-T product candidates. Prior to Poseida, Dr. Ostertag was the CEO of Transposagen, Chief Executive Officer and President of Vindico NanoBioTechnology, and the Executive Vice President at PhenoTech. He is currently on the board of Hera Testing Laboratories.


22. Florian Otto, Cedar Health

Cedar co-founder and CEO, Dr. Florian Otto is on a mission to modernize patients' financial experience. Headquartered in New York City, the company built a patient payment and engagement platform to optimize the medical billing process, making it more personalized, simple, and easy-to-use. Though, for Dr. Otto, this idea wasn't born in vain. After his fiancé fainted and was rushed into the ER, he experienced his own wild ride through the payment process. After swiping his credit card for the copay, they were flooded with a series of confusing bills and unclear payment instructions, which ended in calls from a debt collector. Since launching in 2017, Cedar has quickly become a disruptive player in the patient payment and experience space, propelled by Dr. Otto's goal of bringing healthcare in line with other industries that prioritize transparency and consumer service. Before Cedar, Dr. Otto was the Vice President of Sales at Zocdoc and founded a daily deal company, ClubeUrbano, in Brazil that was eventually acquired by Groupon. After the acquisition, he became Chief Executive Officer of Groupon Brazil, growing the company to one of Groupon's top three international markets.


23. Michel Vounatsos, Biogen

Michel Vounatsos has been CEO and a board member of Biogen since 2017. He originally joined the Company in 2016 as Executive Vice President, Chief Commercial Officer after a 20 year career at Merck. While at Merck, he held leadership positions of increasing responsibility in Europe, China, and the U.S., most recently as President, Primary Care Business Line and Merck Customer Centricity. His role as President encompassed responsibility for Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups. Earlier in his career, Michel held management positions at Ciba-Geigy. He received his CSCT certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his MBA from the HEC School of Management in Paris.


24. Paul Black, Allscripts

Paul Black is the CEO and a director of Allscripts. Prior to joining Allscripts in 2012, Paul spent more than 13 years with Cerner Corporation in various executive positions, retiring as Cerner’s COO in 2007. He started his career with IBM where he spent 12 years in a variety of leadership positions in sales, product marketing and professional services. In Kansas City, Paul spent 16 years as Chairman and as an executive officer of Truman Medical Centers, an academic safety net health system. He currently sits on the boards of Netsmart, the Advancement Board University of Kansas Health System and the Harry S. Truman Presidential Library.


25. Stephen Rusckowski, Quest Diagnotics

Steve Rusckowski is Chairman, President and CEO of Quest Diagnostics. He joined the Company as President and CEO in 2012. Under his leadership, Quest has refocused on its core diagnostic information services business, sold non-core assets, delivered disciplined deployment, including share repurchases and acquisitions, and simplified its organizational structure to better serve customers by removing complexity, speeding decision making and empowering employees. Previously, Stephen was CEO of Philips Healthcare, which became the largest unit of Royal Philips Electronics under his leadership. He joined Philips in 2001 when it acquired the Healthcare Solutions Group he was leading at Hewlett-Packard/Agilent Technologies.


26. Mohamed Shoura, PaxeraHealth

In 2009, Dr. Mohamed Shoura founded PaxeraHealth, a medical imaging solutions provider to solve the most significant healthcare challenges faced by the sector. Today as CEO, Dr. Shoura has led the company to be instrumental in making a real change in the medical IT arena with its cutting edge solutions. PaxeraHealth operates in the US, Middle East, Asia, Africa, and Europe through a vast network of qualified resellers and distributors. Most recently, he created the CoronaCare platform, a complete tracking system for patients with COVID-19 symptoms. Designed to screen and identify high-risk patients in real-time, CoronaCare also reduces the burden placed on call centers while alleviating patients’ worries with educational resources and built-in messaging. Dr. Shoura’s achievements extend beyond PaxeraHealth. In 2016, he founded the award-winning CarePassport platform, a patient-centric program designed to address the challenges of healthcare content management, from medical images to multimedia files, health exams, and visit reports. The industry thought leader’s intense passion for improving the healthcare space with increasingly innovative solutions has garnered Dr. Shoura a series of speaking engagements, most notably with the American College of Radiology between 2013 and 2015.


27. Dr. Bernd Montag, Siemens Healthineers

Bernd Montag, Ph.D., has been CEO of Siemens Healthineers since February 2015. He joined Siemens in 1995 and held various key positions through the years. In 2004, he assumed overall responsibility for computed tomography, and in 2008, he was named President of the Imaging & Therapy Division, which combined the overall business of diagnostic imaging and image-guided therapies. Bernd completed his studies in Physics at the Friedrich-Alexander-University, Erlangen-Nuremberg, and earned a Ph.D. in theoretical multi-particle physics. Siemens Healthineers is a medical technology company with over 170 years of experience and 18,000 patents globally. The Company has 50,000 employees in over 70 countries.


28. Darren Schulte, Apixio

As Chief Executive Officer of Apixio, Dr. Darren Schulte is leading the company into the future of healthcare. By using cognitive computing in the cloud, Dr. Schulte hopes to propel the data-driven revolution in healthcare with Apixio. First joining the company in 2011 as its Chief Medical Officer, Dr. Schulte was appointed CEO in 2014. Founded in 2009, The San Mateo-based company provides computing resolutions for healthcare payers and providers by leveraging AI solutions for risk, quality, and clinical insight. Dr. Schulte is an industry veteran and applies more than 15 years of experience in the healthcare analytics and technology sectors to taking Apixio to the next level. He has co-developed 25 clinical measures endorsed by the National Quality Forum to measure ambulatory care quality using electronic data. Before Apixio, Dr. Schulte was a Business Mentor at Stanford StartX, Vice President of Clinical Strategy at Anvita Health, Executive Vice President of Collaborative Care at Alere Medical, Director of Clinical Affairs and Analytics at Resolution Health and a Resident Physician at UCSF Medical Center. He is also a nationally recognized speaker on the topics of healthcare analytics and quality improvement.


29. Mike Roman, 3M

Mike Roman is the CEO of 3M, a Company he has been with for over 30 years. 3M shares and combines its 46 technology platforms to create differentiated solutions that it brings to market through five business groups: Industrial, Health Care, Safety and Graphics, Electronics and Energy, and Consumer. Before becoming CEO in 2018, Mike was COO and held several other key leadership roles at the Company. In 2014, he assumed leadership of 3M’s largest business group, Industrial, which accounts for one-third of 3M’s global sales. Prior to that, Mike served as chief strategist, where he was instrumental in establishing the company’s future roadmap. He joined 3M in 1988 as a senior design engineer, after five years with the Hughes Aircraft Company.


30. Jeff Fritz, Revel Health

As Chief Executive Officer of Revel Health, Jeff Fritz is defining and leading the company's next strategic leap. Fritz is an industry veteran with over 20 years of experience establishing and leading numerous organizations in the health and wealth sectors. Since joining Revel in 2017, Fritz has moved with a high degree of confidence, which has permeated through the company. "We work 100% at risk," Fritz once told The Observer. "We don't expect our customers to pay for effort; we only ask them to pay for results." As an executive, he is passionate about customer experience methodologies, XaaS, population health initiatives, and modern software technologies. Minneapolis-based Revel Health creates health engagement tools to help health care organizations connect with their customers, ushering in a new era of personalization in health care. Before Revel, Fritz was President of Insite Software, which he joined after that company bought his previous venture, Storyworks1. Before Storyworks1, Fritz founded and later sold health-IT company Lighthouse1, which today is part of Wex Health.


32. Amanda Hansen, AdvancedMD

Amanda Hansen is the president of AdvancedMD. During Amanda’s 13-year tenure at AdvancedMD, she has held multiple positions in business development, sales, service, finance and strategy which have yielded a host of professional accomplishments. She is passionate about increasing operational effectiveness and profitability and driving continual growth while improving patient care and access to healthcare through innovative software solutions. Hansen’s competitive edge, positive outlook and solution-oriented approach have made a noticeable impact on the vision, direction and achievements of the organization. She played a critical role in Global Payments’ recent $700 million acquisition of AdvancedMD from Marlin Equity Partners. Amanda has bachelor’s degree in communication from Brigham Young University.


33. Mike Raab, Ardelyx

When Mike Raab joined Ardelyx as its Chief Executive Officer in 2009, he did so intending to take the specialized biopharmaceutical company to the next level. Over the next ten years, his list of accomplishments grew and came to a head in 2019 as Ardelyx conducted two positive Phase 3 trials and had its first therapy approved. Today, for the first time the company is evolving from a development-stage firm to a commercial entity. Founded in 2007, the San Francisco-based company has focused on the development of novel oral therapeutics to treat mineral metabolism and metabolic disorders. At the heart of what makes Raab a great leader isn’t his long list of achievements but the commitment and compassion he brings to his work. In addition to his current role, Raab has been a Board Member at Amicus Therapeutics for over 16 years. Before joining Ardelyx, Raab was a Partner at New Enterprise Associates, where he specialized in healthcare investments across the biotechnology and pharmaceutical sectors. Prior to this, he was the Senior Vice President of Therapeutics at Genzyme and a Business Development Analyst at Repligen Corporation.


34. Ali Diab, Collective Health

Ali Diab founded Collective Health in 2013 and currently serves as the Company’s CEO. Previously, he was the co-founder and CEO of Qwilt Software and before that headed product management and business operations for Google AdMob. He brings more than 15 years of technology startup and executive management experience as well as a strong personal motivation to improve the quality and cost of company-sponsored health care after experiencing a major health problem while employed at a growing technology company. He began his career at Goldman Sachs soon after which he transitioned to co-founding BuildPoint in the early 2000s. Ali also held senior product management roles with Microsoft and Yahoo. He earned his undergraduate degree from Stanford University and his master’s degree from Oxford University.


35. Tom Langan, Practice Fusion

Tom Langan became CEO of Practice Fusion in 2015. He originally joined the Company in 2014 as its Chief Commercial Officer. Under his leadership, Practice Fusion has experienced rapid growth and success and leads the industry as the most widely used cloud-based EHR. Previously, Tom held executive positions at Symphony Health Solutions and MediMedia. He holds a bachelor’s from Fordham University. Practice Fusion is used by a community of more than 112,000 monthly active healthcare professionals with over 100 million patient records under management. In 2014, Practice Fusion’s EHR facilitated over 56 million patient visits (approximately 6% of all ambulatory visits in the US) and is the fastest growing EHR in the US.


36. Shawn O'Connor, Simulations Plus

As the Chief Executive Officer of Simulations Plus, Shawn O’Connor has continued with his proven track record of strategy definition, optimizing revenue, and creating value for investors. Headquartered in Lancaster, California, Simulations Plus is a premier developer of drug discovery and development software, as well as a leading provider of both preclinical and clinical pharmacometric consulting services. Under his leadership, Simulations Plus has established StrategiesPlus, a COVID-19 ACT Program to speed consulting assistance to any organization involved in coronavirus research, which will provide immediate support for pharmaceutical research and development efforts. Here, O’Connor employs his 30 years of experience spanning multiple industries at companies that range from start-ups to publicly traded companies. With a distinguished career in the pharmaceutical software industry, O’Connor’s resume features long stints at several companies, including being the President, Chief Executive Officer, and a Director of Entelos. Prior to this, he was the Chairman and CEO at Pharsight, President and Chief Operating Officer at QRS, and Chief Financial Officer at Diasonics. He began his career as a Senior Manager at Peat Marwick.


37. Frank Gotthardt, CompuGroup Medical

Frank Gotthardt is Chairman of the Management Board of CompuGroup Medical SE. He built the leading global eHealth company, domiciled in Koblenz, from the very start and has continued to lead and shape it since its founding. Today, 400,000 customers and 4,300 employees worldwide have put their trust in the Company. Frank is the Regional Chairman of the Economic Council of Rhineland-Palatinate and a member of the Federal Executive Board. He privately supports the German bone marrow charity, various development projects and numerous other charitable organizations in the region. He is a sponsor of the long-standing ice hockey club, the Cologne Sharks.


38. Dedi Gilad, Tyto Care

In 2012, Dedi Gilad co-founded Tyto Care, creating the healthcare industry's first all-in-one modular device, telehealth, and AI platform for remote medical exams and visits. Since its inception, Gilad has served as Chief Executive Officer, bringing over 18 years of experience in leadership positions, research and development, healthcare IT, and enterprise systems to the role. Today, as the COVID-19 pandemic sweeps the world, more hospitals and health organizations are expanding their use of the telehealth solution to remotely offer care to quarantined patients in hospitals and isolated people at home. Amidst the pandemic, Tyto Care announced it raised $50 million in a financing round despite the looming economic downturn. Under Gilad's leadership, Tyto Care has experienced rising demand with rapid global telehealth adoption. This upswing saw sales triple in 2019 as well as FDA and CE clearances that have resulted in over 100 partnerships with major health systems, health plans and strategic partners in the US, Europe, Israel, and Asia. Before establishing Tyto Care, Gilad was the General Manager at MDG Medical, Vice President of R&D at WorkplaceIQ, and Vice President R&D at Aman Group.


39. Paul Kaiser, MedeAnalytics

Paul Kaiser is CEO and a board member of MedeAnalytics, which he joined in 2017. The Company provides enterprise-level data analytics solutions to over 1500 clients in the US and UK, including hospitals, health systems, health plans, state Medicaid programs and more. Previously, Paul served as President of TriZetto Provider Solutions, where he led teams to record setting sales and double digit revenue growth while overseeing all aspects of the business including financial performance, business intelligence, sales and product management. Prior to joining TriZetto, he was the director of sales for Cerner Corporation’s managed services portfolio and directed the launch of Cerner’s global managed services solution.


40. Sean Saint, Companion Medical

Sean Saint co-founded Companion Medical in 2014 and has served as its President and Chief Executive Officer since. He has been responsible for assembling the executive team while managing day-to-day operations of the company. Armed with over 15 years of engineering experience in medical devices and various startups, Saint is a trusted industry thought leader. Notably, his personal battle with Type 1 diabetes brings unparalleled empathy to his leadership style. Headquartered in San Diego, California, Companion Medical is an innovative diabetes company that developed the first and only FDA-cleared smart insulin pen system.  InPen combines the freedom of a reusable Bluetooth pen with the intelligence of an intuitive mobile app that helps users administer the right insulin dose, at the right time.  The mobile app simplifies the tracking, monitoring, and calculating required for insulin therapy. Prior to Companion Medical, Saint was the Director of Advanced Technology and Mechanical Engineering at Tandem Diabetes Care, the co-founder and Vice President of R&D at Alure Medical, Engineering Manager at Dexcom, and Senior Engineer at Medtronic/AVE. Currently, Saint has 175 issued and pending patent applications.


41. Laura Schaevitz, Vium

Dr. Laura Schaevitz is the Chief Executive Officer of Vium, the leading innovator for in vivo research, which uses its state-of-the-art Digital Vivarium and Vium Cloud approach to accelerate preclinical drug discovery and development. She joined the company in 2015 as its Global Head of Animal Research and Development before going on to become the Vice President of Scientific Technologies and Chief Scientific Officer. She was appointed CEO at the end of 2019. With over 20 years of experience with in vivo animal studies, Dr. Schaevitz is a crucial member of the Vium team, playing an instrumental role in building its in vivo drug testing platform into a world-leading solution. She oversees the development of animal models and draws upon her experiences as a molecular and behavioral neuroscientist to direct the application of digital metrics to the animal models. Notably, she has utilized a broad spectrum of mouse models, including transgenic and nutrition-induced models of neurodevelopmental disorders such as autism, schizophrenia, Rett syndrome, and blindsight. Today, she serves on the board of the North American 3Rs Collaborative.


42. Shawn Iadonato, Kineta

Dr. Shawn Iadonato is the co-founder and Chief Executive Officer of Kineta, a clinical-stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. Since he was appointed CEO, Dr. Iadonato has focused on fundraising, business development, and working with the board of directors. Under his leadership, Kineta has executed strategic partnerships with biotech giants Genentech and Pfizer. Notably, the company has also established a proprietary screening platform for identifying small molecule innate immune modulators and has advanced novel drug programs in immuno-oncology, neuroscience, and biodefense during his tenure. Before establishing Kineta, Dr. Iadonato co-founded and served as Chief Security Officer of Illumigen Biosciences, where he pioneered a patented drug discovery platform. Dr. Iadonato also led the successful discovery and preclinical development of Illumigen’s anti-hepatitis C drug, which ultimately led to the sale of the company to Cubist Pharmaceuticals, which is now part of Merck & Co. Before Illumigen, Dr. Iadonato managed the Human Genome Center at the University of Washington. He is a co-inventor of over 35 US patents and patent applications.


43. Bill Nordmark, Aver

Bill Nordmark joined Aver Inc. in 2017 as its President and Chief Executive Officer. With his broad expertise in healthcare reimbursement and strategy, the company expected newfound success, though the executive would far exceed these expectations. Under his leadership, Aver developed a new product strategy, including the world’s first episodic-based Bundled Benefit Management solution and Episodic Analytics capabilities. Since joining, he’s been established as the driving force behind all areas of the business and leads the company’s growth efforts to return value to all stakeholders. Headquartered in Columbus, Ohio Aver has been simplifying value-based healthcare by working with healthcare payers, systems, and large practices to design, implement and administer value-based healthcare and bundled payment programs since 2010. Prior to joining Aver, Nordmark was the Chief Growth Officer for Payspan, a leading provider of electronic healthcare payments. Under his leadership, the company experienced record-breaking success, growing from eight health plan customers in 2006 to over 680 customers. Nordmark balances his role with being Vice Chairman of the Board of Representatives at The ALS Association, the only national non-profit organization fighting ALS by leading the way in global research and providing assistance for ALS patients through a nationwide network and fostering government partnerships.


44. Shane Bishop, Catalyst Healthcare

Since founding Catalyst Healthcare in 2008, Bishop transitioned the business of owning and operating automated pharmacies to leading the development and launch of an ecosystem of connected technologies to ensure that medications are taken exactly as prescribed. As a pharmacist and an entrepreneur, Bishop has consistently raised the bar for healthcare innovation. In 2003, he established the first two high volume central-fill pharmacies in Western Canada. He also founded Glenpark IDA Pharmacy in 1996, which is an independent pharmacy in Kelowna that served retail patients and long-term care facilities. In addition to his entrepreneurial work, Bishop has consulted for North America's largest healthcare chains all the way down to independent firms. In 2009, as the Advisory Committee Chair for HRS, he led an independent pharmacy collaboration that used technology, including Catalyst's AdhereNet pharmacy software platform and electronic medication administration record, oneMAR, to ensure quality patient care. Today, as CEO of Catalyst and founding director of Pack4U, the companies he leads work with organizations throughout the U.S. and Canada to improve health outcomes and slash health care costs with in-home medication dispensers, telehealth, connected wearables and patient reported outcome tracking for true remote patient monitoring.


45. Rob MacNaughton, NurseGrid

In 2019, NurseGrid announced the appointment of Rob MacNaughton as its new Chief Executive Officer. Founded in 2013, the Portland-based healthcare startup has grown to become the most recognized brand in the nurse scheduling sector, with over 1 million nurses and other clinical staff utilizing its mobile app. MacNaughton is at the helm of the company's plan to expand its product into more hospitals as a dynamic and performance-driven executive. This year, he did just that as HealthStream acquired NurseGrid for $25 million, which sets to expand its reach into the company's extensive network. MacNaughton's longtime commitment to advancing healthcare is intrinsic to NurseGrid's mission of developing technology that improves nurse satisfaction and simplifies staffing. Before this, he spent almost three years as the Chief Product Officer at Cambia Health Solutions, six years as Vice President of Hospital Operations at Banfield Pet Hospital, and was the Vice President and General Manager of Hollywood Video. In 2006, MacNaughton founded and became the Chief Executive Officer of Columbia Care, a regional home health and hospice supportive care agency.


46. Francis deSouza, Illumina

Francis deSouza was appointed President and CEO of Illumina in 2016. He initially joined the Company as President in 2013. Previously, Francis served as President of Products and Services at Symantec Corporation, where he was responsible for driving the vision for the company’s market-leading portfolio and served in a variety of executive roles. He joined Symantec through the acquisition of IMlogic, where he was co-founder and CEO. Prior to joining IMlogic, Francis was co-founder and CEO of Flash Communications, a provider of corporate instant messaging that was acquired by Microsoft. Following the acquisition, he joined Microsoft and led the team responsible for the development of the company’s enterprise real-time collaboration offerings. Francis is a member of the board of directors for The Walt Disney Company.


47. Hervé Hoppenot, Incyte

Hervé Hoppenot is President, CEO and Chairman of Incyte. Previously, he was the President of Novartis Oncology, where he was responsible for over $11 billion in global sales and an organization of 8,000 employees across 50 countries. His coverage areas included translational medicine, development, approval, and commercialization. Hervé joined Novartis in 2003, and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing. His career began in 1983 when he joined Rhone Poulenc, later known as Aventis. He served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit. Hervé holds a diploma from ESSEC Business School.


48. Bryan Hanson, Zimmer Biomet

Bryan Hanson was named CEO of Zimmer Biomet in 2017. Founded in 1927 Zimmer Biomet is a global leader in musculoskeletal healthcare. The Company designs, manufactures and markets orthopaedic reconstructive products. Previously, Bryan served on Metronic’s Executive Committee and as EVP and President of Metronic’s Minimally Invasive Therapies Group, where he managed over $9 billion in business. Prior to Medtronic, Bryan held various executive roles including Group President of Covidien’s Medical Devices business and Surgical Solutions Group President. He serves on the board of AmeriCares, an emergency response and global health organization committed to saving lives and building healthier futures for people in crisis.


49. Basil Lenzo, INX Software

Basil Lenzo was appointed President and Chief Executive Officer of North America in 2019. He joined INX Software in 2018 as Chief Marketing Officer. With over 25 years of experience in leadership, business frameworks, operations, as well as sales and marketing, Lenzo’s leadership is informed by authenticity and a passion for guiding teams through challenging initiatives. Headquartered in Perth, Western Australia the company provides web and mobile solutions spanning safety, compliance, people logistics, and training in over 23 countries and 21 industries. In 2007, Lenzo founded Datacom in Western Australia, where he led the company as Managing Director, growing the business to an $80 million valuation and over 150 employees. The company was acquired by the Datacom Group in 2015. Lenzo has also held positions as General Manager of Theranostics Australia, which develops targeted molecular diagnostic imaging and therapeutic agents for the diagnosis and treatment of cancers and as General Manager of ASG Group.


50. Clay Siegall, Seattle Genetics

Clay Siegall founded Seattle Genetics in 1998 and today is its President, CEO and Chairman. The Company is known for its pioneering of and continued leadership in antibody-drug conjugates, or ADCs for the treatment of cancer. Since its founding, Seattle Genetics has entered into multiple strategic licenses for its ADC technology with Genentech (Roche), AbbVie, GlaxoSmithKline and Pfizer, that have generated more than $300 million to date. Clay earned a PhD in Genetics from The George Washington University. He has raised nearly $700 million through public and private financings over the course of Seattle Genetics’ history to date. Clay also sits on the boards of Ultragenyx Pharmaceutical, Mirna Therapeutics, and Alder Biopharmaceuticals.